Literature DB >> 19854829

X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists.

Eugene Varfolomeev1, Bruno Alicke, J Michael Elliott, Kerry Zobel, Kristina West, Harvey Wong, Justin M Scheer, Avi Ashkenazi, Stephen E Gould, Wayne J Fairbrother, Domagoj Vucic.   

Abstract

Proapoptotic receptor agonists cause cellular demise through the activation of the extrinsic and intrinsic apoptotic pathways. Inhibitor of apoptosis (IAP) proteins block apoptosis induced by diverse stimuli. Here, we demonstrate that IAP antagonists in combination with Fas ligand (FasL) or the death receptor 5 (DR5) agonist antibody synergistically stimulate death in cancer cells and inhibit tumor growth. Single-agent activity of IAP antagonists relies on tumor necrosis factor-alpha signaling. By contrast, blockade of tumor necrosis factor-alpha does not affect the synergistic activity of IAP antagonists with FasL or DR5 agonist antibody. In most cancer cells, proapoptotic receptor agonist-induced cell death depends on amplifying the apoptotic signal via caspase-8-mediated activation of Bid and subsequent activation of the caspase-9-dependent mitochondrial apoptotic pathway. In the investigated cancer cell lines, induction of apoptosis by FasL or DR5 agonist antibody can be inhibited by knockdown of Bid. However, knockdown of X chromosome-linked IAP (XIAP) or antagonism of XIAP allows FasL or DR5 agonist antibody to induce activation of effector caspases efficiently without the need for mitochondrial amplification of the apoptotic signal and thus rescues the effect of Bid knockdown in these cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19854829      PMCID: PMC2787317          DOI: 10.1074/jbc.M109.040139

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.

Authors:  Kerry Zobel; Lan Wang; Eugene Varfolomeev; Matthew C Franklin; Linda O Elliott; Heidi J A Wallweber; David C Okawa; John A Flygare; Domagoj Vucic; Wayne J Fairbrother; Kurt Deshayes
Journal:  ACS Chem Biol       Date:  2006-09-19       Impact factor: 5.100

Review 2.  The inhibitors of apoptosis (IAPs) as cancer targets.

Authors:  Allison M Hunter; Eric C LaCasse; Robert G Korneluk
Journal:  Apoptosis       Date:  2007-09       Impact factor: 4.677

3.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

Authors:  Sean L Petersen; Lai Wang; Asligul Yalcin-Chin; Lin Li; Michael Peyton; John Minna; Patrick Harran; Xiaodong Wang
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

4.  XIAP discriminates between type I and type II FAS-induced apoptosis.

Authors:  Philipp J Jost; Stephanie Grabow; Daniel Gray; Mark D McKenzie; Ueli Nachbur; David C S Huang; Philippe Bouillet; Helen E Thomas; Christoph Borner; John Silke; Andreas Strasser; Thomas Kaufmann
Journal:  Nature       Date:  2009-07-22       Impact factor: 49.962

5.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

Authors:  James E Vince; W Wei-Lynn Wong; Nufail Khan; Rebecca Feltham; Diep Chau; Afsar U Ahmed; Christopher A Benetatos; Srinivas K Chunduru; Stephen M Condon; Mark McKinlay; Robert Brink; Martin Leverkus; Vinay Tergaonkar; Pascal Schneider; Bernard A Callus; Frank Koentgen; David L Vaux; John Silke
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

6.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.

Authors:  Eugene Varfolomeev; John W Blankenship; Sarah M Wayson; Anna V Fedorova; Nobuhiko Kayagaki; Parie Garg; Kerry Zobel; Jasmin N Dynek; Linda O Elliott; Heidi J A Wallweber; John A Flygare; Wayne J Fairbrother; Kurt Deshayes; Vishva M Dixit; Domagoj Vucic
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

7.  Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.

Authors:  C Adams; K Totpal; D Lawrence; S Marsters; R Pitti; S Yee; S Ross; L Deforge; H Koeppen; M Sagolla; D Compaan; H Lowman; S Hymowitz; A Ashkenazi
Journal:  Cell Death Differ       Date:  2008-01-25       Impact factor: 15.828

Review 8.  Targeting the extrinsic apoptosis pathway in cancer.

Authors:  Avi Ashkenazi
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-20       Impact factor: 7.638

Review 9.  The inhibitor of apoptosis proteins as therapeutic targets in cancer.

Authors:  Domagoj Vucic; Wayne J Fairbrother
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

10.  A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.

Authors:  Alex Gaither; Dale Porter; Yao Yao; Jason Borawski; Guang Yang; Jerry Donovan; David Sage; Joanna Slisz; Mary Tran; Christopher Straub; Tim Ramsey; Vadim Iourgenko; Alan Huang; Yan Chen; Robert Schlegel; Mark Labow; Stephen Fawell; William R Sellers; Leigh Zawel
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

View more
  27 in total

Review 1.  Fas death receptor signalling: roles of Bid and XIAP.

Authors:  T Kaufmann; A Strasser; P J Jost
Journal:  Cell Death Differ       Date:  2011-09-30       Impact factor: 15.828

Review 2.  Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases.

Authors:  Madhu Ramaswamy; Min Deng; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

3.  Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Li-Qun Gu; Feng-Ying Li; Lin Zhao; Yun Liu; Qian Chu; Xun-Xiong Zang; Jian-Min Liu; Guang Ning; Yong-Ju Zhao
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

Review 4.  Small-molecule SMAC mimetics as new cancer therapeutics.

Authors:  Longchuan Bai; David C Smith; Shaomeng Wang
Journal:  Pharmacol Ther       Date:  2014-05-16       Impact factor: 12.310

5.  Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.

Authors:  Christy C Ong; Adrian M Jubb; Peter M Haverty; Wei Zhou; Victoria Tran; Tom Truong; Helen Turley; Tom O'Brien; Domagoj Vucic; Adrian L Harris; Marcia Belvin; Lori S Friedman; Elizabeth M Blackwood; Hartmut Koeppen; Klaus P Hoeflich
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

6.  cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production.

Authors:  N Vanlangenakker; T Vanden Berghe; P Bogaert; B Laukens; K Zobel; K Deshayes; D Vucic; S Fulda; P Vandenabeele; M J M Bertrand
Journal:  Cell Death Differ       Date:  2010-11-05       Impact factor: 15.828

7.  Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.

Authors:  Hope M Amm; Tong Zhou; Adam D Steg; Huichien Kuo; Yufeng Li; Donald J Buchsbaum
Journal:  Mol Cancer Res       Date:  2011-02-25       Impact factor: 5.852

Review 8.  Targeting IAP proteins for therapeutic intervention in cancer.

Authors:  Simone Fulda; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

9.  cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation.

Authors:  Rosanna Lau; Min Ying Niu; M A Christine Pratt
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

10.  Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells.

Authors:  Marina Pisano; Gabriella Pagnan; Maria Antonietta Dettori; Sara Cossu; Irene Caffa; Ilaria Sassu; Laura Emionite; Davide Fabbri; Michele Cilli; Fabio Pastorino; Giuseppe Palmieri; Giovanna Delogu; Mirco Ponzoni; Carla Rozzo
Journal:  Mol Cancer       Date:  2010-06-03       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.